
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Agilent Technologies Inc (A)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: A (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $138.17
1 Year Target Price $138.17
9 | Strong Buy |
2 | Buy |
9 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.49% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 35.50B USD | Price to earnings Ratio 29.13 | 1Y Target Price 138.17 |
Price to earnings Ratio 29.13 | 1Y Target Price 138.17 | ||
Volume (30-day avg) 20 | Beta 1.22 | 52 Weeks Range 96.23 - 153.19 | Updated Date 08/28/2025 |
52 Weeks Range 96.23 - 153.19 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-19 | When Before Market | Estimate 1.37 | Actual 1.37 |
Profitability
Profit Margin 17.59% | Operating Margin (TTM) 23.56% |
Management Effectiveness
Return on Assets (TTM) 8.46% | Return on Equity (TTM) 18.88% |
Valuation
Trailing PE 29.13 | Forward PE 19.16 | Enterprise Value 35724642566 | Price to Sales(TTM) 5.36 |
Enterprise Value 35724642566 | Price to Sales(TTM) 5.36 | ||
Enterprise Value to Revenue 5.39 | Enterprise Value to EBITDA 20.31 | Shares Outstanding 284064992 | Shares Floating 283056298 |
Shares Outstanding 284064992 | Shares Floating 283056298 | ||
Percent Insiders 0.29 | Percent Institutions 92.32 |
Upturn AI SWOT
Agilent Technologies Inc

Company Overview
History and Background
Agilent Technologies Inc. was founded in 1999 as a spin-off from Hewlett-Packard. It quickly established itself as a leader in life sciences, diagnostics, and applied chemical markets.
Core Business Areas
- Life Sciences and Applied Markets Group (LSAG): Provides application-focused solutions that include instruments and software, primarily for the life science and applied chemical markets.
- Diagnostics and Genomics Group (DGG): Offers diagnostic and genomic solutions, primarily for the clinical and diagnostic markets.
- Agilent CrossLab Group (ACG): Provides services, consumables, and software to support the installed base across all of Agilentu2019s product lines.
Leadership and Structure
Padraig McDonnell is the current CEO. Agilent has a functional organizational structure with centralized departments and business groups focused on specific markets.
Top Products and Market Share
Key Offerings
- Liquid Chromatography Mass Spectrometry (LC/MS): LC/MS instruments are used for identifying and quantifying compounds in various samples. Agilent is a leading player in this market. Market share varies by specific LC/MS segment, but is estimated to be in the 20-30% range. Competitors include Thermo Fisher Scientific (TMO) and Waters Corporation (WAT).
- Gas Chromatography (GC): GC instruments are used for separating and analyzing volatile compounds. Agilent holds a significant market share in GC, estimated between 30-40%. Competitors include Thermo Fisher Scientific (TMO) and PerkinElmer (PKI).
- Genomics Solutions: Agilent's genomics solutions include microarrays, next-generation sequencing (NGS) library preparation, and target enrichment. Market share in genomics is more fragmented, but Agilent holds a significant position with revenues greater than 5% of total market. Competitors include Illumina (ILMN) and Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The analytical instrument industry is driven by increasing demand for testing and analysis in life sciences, diagnostics, environmental monitoring, and food safety. Growth is also fueled by technological advancements and increasing regulatory requirements.
Positioning
Agilent is a leading provider of analytical instruments and solutions. Its competitive advantages include a broad product portfolio, strong brand reputation, and global reach.
Total Addressable Market (TAM)
The total addressable market for analytical instruments is estimated to be around $60 billion. Agilent is positioned to capture a significant portion of this TAM through its diverse product offerings and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Broad product portfolio
- Global reach
- Innovation in analytical instruments
- Recurring revenue from services and consumables
Weaknesses
- High R&D expenses
- Dependence on specific markets
- Exposure to economic cycles
- Complex product portfolio can create internal inefficiencies.
Opportunities
- Growing demand for diagnostics and genomics
- Expansion into emerging markets
- Development of new technologies
- Strategic acquisitions to expand product offerings
Threats
- Intense competition
- Technological obsolescence
- Economic downturns
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Waters Corporation (WAT)
Competitive Landscape
Agilent competes with a variety of companies in the analytical instrument market. Its competitive advantages include a broad product portfolio, strong brand reputation, and global reach. However, it faces intense competition from larger and more diversified players like Thermo Fisher Scientific.
Major Acquisitions
Resolution Bioscience
- Year: 2021
- Acquisition Price (USD millions): 550
- Strategic Rationale: Expanded Agilent's presence in the NGS-based cancer diagnostics market.
BioTek Instruments
- Year: 2019
- Acquisition Price (USD millions): 1050
- Strategic Rationale: Expanded Agilent's cell analysis portfolio and increased its presence in the drug discovery market.
Growth Trajectory and Initiatives
Historical Growth: Agilent has experienced steady growth in recent years, driven by strong demand in its core markets and successful execution of its growth strategy.
Future Projections: Analysts project continued growth for Agilent, driven by increasing demand for analytical instruments and solutions. Revenue growth is expected to be in the mid-single digits, with continued margin expansion.
Recent Initiatives: Recent strategic initiatives include acquisitions to expand product offerings, investments in R&D to develop new technologies, and expansion into emerging markets.
Summary
Agilent is a strong company with a leading position in the analytical instrument market. It benefits from a broad product portfolio, strong brand reputation, and recurring revenue streams. While facing competition, its focus on innovation and strategic acquisitions positions it well for future growth. A key area to watch is its ability to maintain margins in a competitive environment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Agilent Technologies Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports (e.g., BCC Research, MarketsandMarkets)
- Analyst Reports (e.g., Morgan Stanley, Goldman Sachs)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agilent Technologies Inc
Exchange NYSE | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 1999-11-18 | CEO, President & Director Mr. Padraig McDonnell | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 18000 | Website https://www.agilent.com |
Full time employees 18000 | Website https://www.agilent.com |
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. This segment also offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies. The Diagnostics and Genomics segment provides genomics, contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses; and cell analysis plate based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, and related consumables. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.